I think I threw 'em a knock out punch!

RR- here's something that the 100mil might be useful for:

http://www.upenn.edu/pennnews/news/penn-researchers-improve-living-tissues-3d-printed-vascular-networks-made-sugar

It solves some of the vascular issues of thicker tissues.

Heard this: like owning a plank of the Mayflower, I like it.

Lets repeat: ONVO IS PROPRIETARY, SMART

Not my intent. I am a serious long and was trying to provide info on a possible short scenario: sp doubling on up listing without a revenue change, company equity offering immediately after and a non-existent % short float all spelled I need to prepare, as these things will have gotten the attention of the professional shorts. This is normal for a company in Organovo's position, no need to over react. Professional shorts are an inevitable virus in the progression of the company. If I hadn't already filled my position at 3.81 avg, I'd be buying more in the coming days.

This is the official validation of the information posted on the S-3. With this filing, it appears the company is moving forward with some type of equity offering on the 100mil they told us about. Necessary for the company's plans. Today's action could be the hedges knowing what's coming, and are preparing to take their short position to get cheaper shares from the company offer to cover after they drive it down. This is one way the shorts make their money, and please prove me wrong.

Seems that Organovo is commanding the spotlight recently, especially at seeking alpha. 3 new articles in the last few days. I know there are a lot of varying opinions here about this site, but the subscribers there are knowledgeable and they bring awareness, enthusiasm, and new money to our stock. I personally read every article and participate in the discussion.

However, I still find this article, written at the end of last year, the most comprehensive articulation on Organovo to date.

http://bionapcfa.blogspot.com/2012/12/organovo-seeks-to-clean-up-balance.html

Happy Sunday to you all, and thanks for link bhenchoddonga
Knowledge is power.

I just went through a financier raid on one of my other speculative stocks. 8mil shares issued to a convertible note. The financial investor drove the price down as that convert date drew near. It was there in the original agreement but I didn't understand what it was. Shame on me.

The not good variety are what I'm after and how they might use those on ONVO.
Always prepared, never surprised.
Thanks for the input.

Thanks for the reply. I have started to look into the options plays, seems a cleaner way to make money on premiums and if the sp goes down. Lots to learn.

Thanks for the starter supposition, my motivator here is making money also but I was kinda looking for a little more in-depth analysis. I am not a trader, but I understand why you guys do what you do. Seems to me the shorts have an intricate part in setting your channel, so a closer look at their mind set was my question and thought for the weekend.

Know your adversary, he will make you stronger. peace

I'm educating myself on that reality, so i'm curious...

What are the opinions on why shorts short?
TIA

Anyone planning on going to the shareholders meeting?

That's what I'm seeing also. Might be they haven't updated, last reporting date was 3/31/13.

Gotta think that tuts have bought in since the uplist.

I agree, shorting this technology would be a crime against humanity.

The article on SA said to expect 15 mil shares short, 25% of the float.
Think that's coming?

Thanks for the link, verified my data.

This is interesting.

http://www.nasdaq.com/symbol/onvo/short-interest

Anyone have a different source?

Where does your mind go my friend?
I like it.

"As constructs move into clinical and commercial settings, full compliance with the FDA’s CGTP (Current Good Tissue Practices) and CGMP (Current Good Manufacturing Practices) guidelines will be required."

This will be both Organovo's and their collaborators responsibility.

Contrarian opinions are necessary to a complete understanding. We all should be aware of the other sides intentions and arguments. It makes us better prepared to handle the movement.

Check the comments section later today to see how that community will counter the authors opinions. They won't let this go without debate.

Awesome link sir! Everything you need to know about gaps.
I personally feel giving the chance to educate someone who asks is a sign of an enlightened mind.
Good to see that is the case here.

Any of you fine traders have time to answer this informative question?
peace

That's a good opinion sir.
In my world, Nothing good has ever came from banks.

It was an awesome day in San Diego +12.6%

Up listing has created a new animal, hasn't it? I was comfortable with the old range but now must wait until the new channel is set. Where do you think the base will land?

I see we trade the same sector. Gotta tell ya, sold most of my Worlds for Blue Calypso this morning ;)

After reading court doc 51, I opened my first position at .16

http://www.scribd.com/mobile/doc/155318996

Anyone familiar with lag time of pacer doc filings in eastern Texas?

I agree that the wording is standard, however, I have only seen this with companies that take a serious stance on self preservation. One could take these formal inclusions in the SEC filings, and statements like: "We plan to aggressively pursue a number of new areas of application for our technologies over time, and will continue to inform you of our plans. All of our deliberations about future directions and future financing will be considered from the perspective of our goal of maximizing long term shareholder value" as lip service from corporate executives bent on lining the pockets of a few. Always a possibility, this is Wall Street.

I don't see things shaking out that way. To many concerted efforts to bring this company into existence. Dr. Forgacs leaving worried me for a minute until I found he was starting a company, Modern Meadows, they are going to print food...his son remains on the board of Organovo.

JMO peace

You have brought up 3 very interesting ideas in your wonderin my friend.

1. "Think ONVO will be around long enough to overtake the big boys in pharma?"
Good question, the discussion on takeovers needs to continue. Both ways for sure.

2. "Why buy cancer drugs when you can just swap out any tissue with healthy printed structures."
This is Organovo's best case future path. A total shift in health care. My only fear is Pharma realizing this and take the attitude of this technology needs to go in the 'vault of things that can kill us' never to be seen again. 2B buyout would be a crime.

3a."I also wonder if they'll ever sell the printers"
As long as there is a royalty structure in place, yes. There will be profit from manufacturing the hardware.
b. "how hard they are going to be to use when Autodesk finishes the user interface software?"
Best question, the Autodesk partnership is the last piece of the NovoGen printer. The operating software they are writing will allow a surgeon to print right in the operating room. This to me will be an important catalyst for this company.

Looking forward to the discussion on these important topics, thanks for letting me share my opinions. peace

You are seeing the correlation correctly.
Isn't it cool how you take a simple(advanced) idea and put it with really smart people and watch what their imagination can do.

This is how I found Organovo. I come from the I/P sector and there you read patents, its your product. When I came across these from the University of Missouri-Columbia:
• “Self-Assembling Cell Aggregates and Methods of Making Engineered Tissue Using the Same” US 10/590,446 and 8,241,905.
• “Self-Assembling Multicellular Bodies and Methods of Producing a Three-Dimensional Biological Structure Using the Same” PCT/US 2009/48 and US 8,143,05
I went say what?! I've been in awe every since.

If anyone is interested in reading these themselves, here's the link.
http://www.uspto.gov/patents/process/search/index.jsp

peace

ExplainingTheFuture is an awesome site full of ideas to expand your thinking.

In Situ printing being done at Wake Forrest will be a miracle for the health of millions of patients.
Organovo has their NovoGen MMX printer at Wake Forrest and has multiple collaborations with academia. This is where one can find future discoveries and patent filings.

"In 2011 and 2012 we provided NovoGen MMX BioprintersTM for use by the following institutions, among others, for research purposes: Harvard Medical School, Wake Forest University, and the Sanford Consortium for Regenerative Medicine (“SCRM”). The SCRM is a new institution which opened in November, 2011, comprised of faculty from the Salk Institute, The Scripps Research Institute, the University of California, San Diego, Sanford-Burnham Medical Research Institute, and La Jolla Allergy and Immunology Institute. We believe that the use of our bioprinting platform by major research institutions will increase the understanding of the technological and research value of the platform, ultimately creating future opportunities for intellectual property licensing."

Yes sir, and it looks like we will be there for our share!

More facts from Organovo's S-3 concerning a possible takeover attempt.

"delay, defer or prevent a change in control;"

"discourage acquisition proposals or tender offers for our shares and, as a consequence, inhibit fluctuations in the market price of our shares that could result from actual or rumored takeover attempts."

One could interpret from Organovo's statements that they are going to prevent any type of takeover.

IMO, why sell the cow when the milk is going to produce $8-10K per assay. Pharma's will need 48-96 well assay kits per specific drug application. Keith is keeping this company.

Here's some food for thought. From Organovo's S-3

Anti-Takeover Effects of Provisions of our Charter Documents and Delaware Law

"Anti-takeover provisions of Delaware law and in our certificate of incorporation and our bylaws may discourage, delay or prevent a change in control of our company, even if a change in control would be beneficial to our stockholders."

Some interesting news from the company.

"Dr. Heyman is an experienced life science executive who is currently chief executive officer of Aragon Pharmaceuticals, which he co-founded in 2009. In June 2013, Aragon announced a definitive agreement with Johnson and Johnson whereby Aragon will be acquired for up to $1 billion dollars in total transaction value"

Hello Dr. Heyman, you have done well. This now makes 4/5 BOD Independent.

Good public source of information on Organovo. The people over there seem like they have a grasp.
Especially like the read on Organovo's beginning via the reverse merger.
Thanks for the link.

This post comes from those watching from the gallery.
The level of discussion the last few days has been outstanding, and I personally have been getting quite a few new lessons on TA, charts and fundamentals. After reading the merger agreement and following the volume from the new shares and shareholders, it was nice to have you guys confirm what I saw with the technicals. I opened my position at 1.65 and added today at 1.76. I appreciate all the hard work(or should I say fun) you guys have brought here. Please keep up the good work and lessons. Thanks.